CARING BRANDS INC (CABR)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$0.75-16.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · CABR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“With five issued U.S. patents protecting our flagship platforms across multi-billion-dollar hair care and dermatology markets, our immediate operational focus is translating this strong legal founda…
Stated in 1 of 1 supplied quarters. Management reported: ““With five issued U.S. patents protecting our flagship platforms across multi-billion-dollar hair care and dermatology markets, our immediate operational focus is translating this strong legal foundation into scalable commercial opportunities, advancing operational readiness, empowering existing partners like Taisho, and securing new licensing agreements globally.”” “Dr. Glynn Wilson, CEO of Caring Brands, commented, “This expanded agreement reflects our confidence in SCPL’s commercial execution and our shared vision for bringing these clinically validated technologies to patients across high-growth international markets in order to improve our revenue stream.”” Revenue was $0.000 million in 2025-Q4.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““With five issued U.S. patents protecting our flagship platforms across multi-billion-dollar hair care and dermatology markets, our immediate operational focus is translating this strong legal founda…”
After giving effect to the $3,852,686 Series A reclassification and $6,999,900 of net PIPE proceeds, pro forma stockholders’ equity is approximately $8,220,419.
Stated in 1 of 1 supplied quarters. Management reported: “After giving effect to the $3,852,686 Series A reclassification and $6,999,900 of net PIPE proceeds, pro forma stockholders’ equity is approximately $8,220,419.” “The Company previously disclosed that it is not in compliance with the stockholders’ equity requirement of Nasdaq Listing Rule 5550(b) and that the Nasdaq Staff issued a delisting determination, which the Company has appealed to a Hearings Panel.”
“The Company previously disclosed that it is not in compliance with the stockholders’ equity requirement of Nasdaq Listing Rule 5550(b) and that the Nasdaq Staff issued a delisting determination, whic…”
Subsequent to August 31, 2026, the Company completed a preferred-stock private investment in public equity (PIPE) with gross proceeds of $7,149,900.
Stated in a supplied disclosure. Management reported: “Subsequent to August 31, 2026, the Company completed a preferred-stock private investment in public equity (PIPE) with gross proceeds of $7,149,900.” “For purposes of this presentation, estimated offering costs of $150,000 are recorded as a reduction of additional paid-in capital, resulting in net cash proceeds and an increase in stockholders’ equity of $6,999,900.”
Advance commercialization and licensing of patented Hair Enzyme Booster and Photocil platforms across global markets.
Raise capital through private investment in public equity (PIPE) offerings to improve stockholders' equity and Nasdaq compliance.
Over the trailing year it converted 0.31x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.